Stay updated on Comparing BI 695500 vs. Rituximab in Follicular Lymphoma: Clinical Trial
Sign up to get notified when there's something new on the Comparing BI 695500 vs. Rituximab in Follicular Lymphoma: Clinical Trial page.

Latest updates to the Comparing BI 695500 vs. Rituximab in Follicular Lymphoma: Clinical Trial page
- Check7 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2 on the ClinicalTrials.gov error page.SummaryDifference0.2%

- Check14 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check21 days agoNo Change Detected
- Check35 days agoChange DetectedThe Study Record page now shows a 403 Forbidden error, replacing the detailed study information with a minimal error screen and hiding most of the usual content and links.SummaryDifference18%

- Check56 days agoChange DetectedThe page's revision tag was updated from v3.6.5 to v3.6.6, reflecting a minor version update to the page rendering. It represents a metadata change rather than a modification to study content.SummaryDifference0.0%

- Check63 days agoChange DetectedA Related Info section was added, showing sponsor-related context such as Boehringer Ingelheim and a 'Helpful Links Provided by' entry. The new content also includes drug and device information, study documents, and helpful links as part of the Related Info area.SummaryDifference0.2%

- Check77 days agoChange DetectedThe page displays Revision: v3.6.5, indicating a new site version.SummaryDifference0.0%

Stay in the know with updates to Comparing BI 695500 vs. Rituximab in Follicular Lymphoma: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Comparing BI 695500 vs. Rituximab in Follicular Lymphoma: Clinical Trial page.